Viatris (VTRS) Income from Continuing Operations (2019 - 2026)

Viatris' (VTRS) quarterly Income from Continuing Operations came in at 176400000.0 in Q1 2026, up 105.8% year-on-year from 85714778.61 in Q1 2025, and up 151.87% quarter-over-quarter from 340100000.0 in Q4 2025.

Viatris (VTRS) Income from Continuing Operations (2019 - 2026) Analysis & Trends

Viatris' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 176400000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 105.8% year-over-year to 176400000.0 in Q1 2026; TTM through Mar 2026 was 296500000.0, a 92.18% increase from a year earlier, with the FY2025 full-year figure at 3514900000.0, down 454.23% from the prior year.
  • Income from Continuing Operations grew to 176400000.0 in Q1 2026 per VTRS's latest filing, from 340100000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1011200000.0 in Q4 2022 and bottomed at 3042000000.0 in Q1 2025.
  • The 5-year median for Income from Continuing Operations is 113900000.0 (2024), against an average of 108200000.0.
  • Across the five-year window, Income from Continuing Operations soared 483.32% in 2022 and slumped 2770.76% in 2025, its largest moves.
  • Year by year, Income from Continuing Operations stood at 1011200000.0 in 2022, then slumped by 175.71% to 765600000.0 in 2023, then jumped by 32.54% to 516500000.0 in 2024, then jumped by 34.15% to 340100000.0 in 2025, then jumped by 151.87% to 176400000.0 in 2026.
  • Per Business Quant, the three latest VTRS Income from Continuing Operations figures stand at 176400000.0 (Q1 2026), 340100000.0 (Q4 2025), and 128200000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn -22.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 176.40 Mn
Dec 31, 2025 -340.10 Mn
Sep 30, 2025 -128.20 Mn
Jun 30, 2025 -4.60 Mn
Mar 31, 2025 -3.04 Bn
Dec 31, 2024 -516.50 Mn
Sep 30, 2024 94.80 Mn
Jun 30, 2024 -326.40 Mn
Mar 31, 2024 113.90 Mn
Dec 31, 2023 -765.60 Mn
Sep 30, 2023 331.60 Mn
Jun 30, 2023 264.00 Mn
Mar 31, 2023 224.70 Mn
Dec 31, 2022 1.01 Bn
Sep 30, 2022 354.30 Mn
Jun 30, 2022 313.90 Mn
Mar 31, 2022 399.20 Mn
Dec 31, 2021 -263.80 Mn
Sep 30, 2021 311.50 Mn
Jun 30, 2021 -279.20 Mn